In the emerging field of stem cell transplantation for regenerative cell therapy, it is generally taken for granted that such donor stem cells will behave like any other differentiated cells immunologically when transplanted into histocompatibility-mismatched recipients.
1Thus, the current preferred approach of using autologous stem or progenitor cells for myocardial regeneration, both experimentally and clinically, aims to avoid immune rejection of donor cells, which can be expected after allogeneic or xenogeneic transplantation. The primary rationale in favoring research on “therapeutic cloning” is to avoid immune rejection after the transplantation of cells derived from embryonic stem cells. Thus, in any experimental studies involving transplantation of such cells across histocompatibility barriers, the investigators automatically assume that either immunosuppression will be required or the use of immunodeficient recipients (such as SCID or nude mouse) will be mandatory.
- Burnet F.M.
The clonal selection theory of acquired immunity. Vanderbilt University Press, Nashville, TN1959
- Toma C.
- Pittenger M.F.
- Cahill K.S.
- Byrne B.J.
- Kessler P.D.
Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart.
Circulation. 2002; 105: 93-98
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The Journal of Heart and Lung Transplantation
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- The clonal selection theory of acquired immunity. Vanderbilt University Press, Nashville, TN1959
- Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart.Circulation. 2002; 105: 93-98
- Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep.Nature Med. 2000; 6: 1282-1286
- Human mesenchymal stem cells persist, demonstrate site-specific multipotential differentiation, and are present in sites of wound healing and tissue regeneration after transplantation into fetal sheep.Blood Cells Molec Dis. 2001; 27: 601-604
- Xenotransplant cardiac chimera.Ann Thorac Surg. 2002; 74: 19-24
- Xenogenic bone marrow stromal cell implantation into acutely ischemic myocardium attenuates deterioration in cardiac function.Circulation. 2002; 106: II-131
- Cellular cardiomyoplasty with allogeneic mesenchymal stem cells results in improved cardiac performance in a swine model of myocardial infarction.Circulation. 2001; 104: II-599
- Multilineage differentiation of transplanted allogenic mesenchymal stem cells in a porcine model of recent myocardial infarction improves left ventricular function.Circulation. 2002; 106: II-34
- Cellular cardiomyoplasty.in: Kipshidze N. Serruys P.W. Handbook of cardiac cell transplantation. Martin Dunitz, London2004
- Transplantation of embryonic stem cells improves cardiac function in postinfarcted rats.J Appl Physiol. 2002; 92: 288-296
- Long-term improvement of cardiac function in rats after infarction by transplantation of embryonic stem cells.J Thorac Cardiovasc Surg. 2003; 125: 361-369
- Stem cell differentiation requires a paracrine pathway in the heart.FASEB J. 2002; 16: 1558-1566
- Transient immunosuppression is effective for xenotransplantation of human myoblasts for cardiac repair in a porcine heart mode.Circulation. 2002; 106: 69
- Preimplantation-stage stem cells induce long-term allogeneic graft acceptance without supplementary host conditioning.Nature Med. 2002; 8: 171-178
- Embryonic stem cell-derived cardiomyocyte transplantation into the infracted myocardium.Heart Surg Forum. 2002; 6: 1
- Stromal cell modulation of the immune system. A potential role for mesenchymal stem cells.Graft. 2000; 3: 324-328
- Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.Exp Hematol. 2002; 30: 42-48
- Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli.Blood. 2002; 99: 3838-3843
- Human mesenchymal stem cells induce unresponsiveness in preactivated, but not naive alloantigen-specific T cells.Exp Hematol. 1999; 27: 122
- Stem cell medicine encounters the immune system.Nature Rev Immunol. 2002; 2: 859-871
- Xenotransplantation—2000.J Clin Pathol. 2000; 53: 44-48
- Direct cell-cell interaction of cardiomyocytes is key for bone marrow stromal cells to go into cardiac lineage in vitro.J Thorac Cardiovasc Surg. 2003; 125: 1470-1480
- Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion.Nature. 2002; 416: 542-545
- Changing potency by spontaneous fusion.Nature. 2002; 416: 545-548
- Multilineage potential of adult human mesenchymal stem cells.Science. 1999; 284: 143-147
- Rapid expansion of recycling stem cells in cultures of plastic-adherent cells from human bone marrow.Proc Natl Acad Sci USA. 2000; 97: 3213-3218
- Pluripotency of mesenchymal stem cells derived from adult marrow.Nature. 2002; 418: 41-49
- Shattuck Lecture—diversity of the immune repertoire and immunoregulation.N Engl J Med. 2003; 348: 1017-1026
- T cell costimulatory pathways.Exp Opin Biol Ther. 2003; 3: 227-250
- Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment.Nature Med. 2000; 6: 464-469
- An innate sense of danger.Sem Immunol. 1998; 10: 399-415
- Natural adjuvants.Nature Med. 1999; 5: 1249-1255
- The danger model.Science. 2002; 296: 301-305
- Danger.Sem Immunol. 2000; 12: 231-238
- Adult stem cell therapy for heart failure.Exp Opin Biol Ther. 2003; 3: 215-226
Accepted: November 12, 2004
Received in revised form: October 14, 2004
Received: July 15, 2004
© 2005 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.